OSCR
Oscar Health, Inc.
OSCR has the edge over VREX overall, supported by stronger fundamentals and stronger valuation.
VREX
Varex Imaging Corporation
VREX has lower modeled downside risk, despite its lower overall score.
OSCR Fundamentals
| Metric | Status |
|---|---|
| Strong | |
| Healthy | |
| Strong | |
| Strong |
OSCR's revenue, profitability, cash flow and balance sheet are all currently healthy.
VREX Fundamentals
| Metric | Status |
|---|---|
| Stable | |
| Healthy | |
| Under pressure | |
| Stable |
VREX's profitability is currently healthy, and its revenue and balance sheet are stable, but its cash flow is under pressure.
OSCR PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Forward | 12x | $31.94 | — |
| Current | 13x | $31.94 | — |
| Cheap | 21x | $52.73 | +65% |
| Fair | 35x | $87.23 | +173% |
| Expensive | 130x | $322 | +907% |
Historical ranges are pointers, not guarantees.
OSCR has the edge over VREX in the historical PE scenario, which offers more potential upside but is not a forecast.
VREX PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Cheap | 18x | $9.16 | -50% |
| Forward | 20x | $18.27 | — |
| Fair | 31x | $16.23 | -11% |
| Current | 35x | $18.27 | — |
| Expensive | 69x | $35.92 | +97% |
Historical ranges are pointers, not guarantees.
VREX's PE is in its fair range at 35x. If earnings grow as analysts expect, today's price would be 20x next year's earnings, in its cheap range.
OSCR Forward outlook
| Metric | Outlook |
|---|---|
| Improving | |
| Strong growth | |
| Strong growth | |
| Strongly improving | |
| Limited | |
| Moderate |
OSCR has the edge over VREX on the outlook, with more favorable revenue and profitability expectations.
VREX Forward outlook
| Metric | Outlook |
|---|---|
| Strongly improving | |
| Growth | |
| Stable | |
| Stable | |
| Limited | |
| High |
Analysts expect VREX's earnings to grow, with its revenue and profitability holding steady.
OSCR Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $2.61 | +5.6% |
| Q3 2026 | $2.47 | +$3.47 |
| Q2 2026 | $1.45 | +$2.14 |
| Q1 2026 | -$0.54 | -235% |
| Q4 2025 | -$1.69 | -1790% |
| Q3 2025 | -$1.00 | -$0.92 |
| Q2 2025 | -$0.69 | -$0.54 |
| Q1 2025 | $0.40 | +$0.82 |
| Q4 2024 | $0.10 | +$1.32 |
OSCR has the edge over VREX on earnings, with more consistent year-over-year improvement.
VREX Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $0.91 | +75% |
| Q2 2026 | $0.52 | +$3.73 |
| Q1 2026 | -$2.00 | -$0.97 |
| Q4 2025 | -$1.64 | -$0.47 |
| Q3 2025 | -$1.70 | -$0.53 |
| Q2 2025 | -$3.21 | -534% |
| Q1 2025 | -$1.03 | -212% |
| Q4 2024 | -$1.17 | -218% |
| Q3 2024 | -$1.17 | -208% |
VREX has returned to profit: it earned $0.52 per share over the past year, after losing money the year before.
OSCR Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $5.1B | +72% |
| Q2 2026 | $4.9B | +70% |
| Q1 2026 | $4.6B | +53% |
| Q4 2025 | $2.8B | +17% |
| Q3 2025 | $3B | +23% |
| Q2 2025 | $2.9B | +29% |
| Q1 2025 | $3B | +42% |
| Q4 2024 | $2.4B | +67% |
OSCR has the edge over VREX on sales, with more consistent year-over-year improvement.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 3.5% | +7.8 points |
| Q2 2026 | 8% | +16 points |
| Q1 2026 | 15% | +5.4 points |
| Q4 2025 | -12% | -5.7 points |
| Q3 2025 | -4.3% | -2.3 points |
| Q2 2025 | -8.1% | -11 points |
| Q1 2025 | 9.8% | +1.1 points |
| Q4 2024 | -6.2% | +4 points |
OSCR's operating margin was 3.5% last quarter, up 7.8 points from the same quarter a year ago.
VREX Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q2 2026 | $210.5M | +3.7% |
| Q1 2026 | $216M | +1.5% |
| Q4 2025 | $209.6M | +4.9% |
| Q3 2025 | $228.9M | +11% |
| Q2 2025 | $203M | -2.9% |
| Q1 2025 | $212.9M | +3.2% |
| Q4 2024 | $199.8M | +5.2% |
| Q3 2024 | $205.7M | -9.5% |
VREX's revenue has grown year over year for four quarters in a row: $211M last quarter, up 3.7% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q2 2026 | 11% | +51 points |
| Q1 2026 | 6.7% | -3.7 points |
| Q4 2025 | 7.3% | +1.7 points |
| Q3 2025 | 8.6% | +3.3 points |
| Q2 2025 | -40% | -44 points |
| Q1 2025 | 10% | +6.7 points |
| Q4 2024 | 5.6% | +3.4 points |
| Q3 2024 | 5.3% | -5.4 points |
VREX has the edge over OSCR on profitability, with a higher operating margin.
OSCR Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$1.2B | -$238.2M |
| Q2 2026 | $2.1B | +316% |
| Q1 2026 | $2.6B | +200% |
| Q4 2025 | $662.8M | +95% |
| Q3 2025 | -$973.7M | -$466M |
| Q2 2025 | $499.8M | +2.1% |
| Q1 2025 | $869.5M | +38% |
| Q4 2024 | $340M | +17% |
OSCR has the edge over VREX on cash generation, producing positive trailing cash flow while its opponent burns cash.
VREX Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q2 2026 | $12M | +757% |
| Q1 2026 | -$7.7M | -179% |
| Q4 2025 | -$26.8M | -606% |
| Q3 2025 | $2.3M | -88% |
| Q2 2025 | $1.4M | -58% |
| Q1 2025 | $9.8M | +$12.5M |
| Q4 2024 | $5.3M | +$5.4M |
| Q3 2024 | $19.9M | -52% |
VREX's free cash flow was −$20M over the past year, against $36M the year before.
OSCR Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +3.9% | +13M shares |
| 1 year | +34% | +87.2M shares |
| 3 years | +55% | +123M shares |
| 5 years | +66% | +138M shares |
| Available history | +71% | +143M shares |
OSCR has 346M diluted shares, up 34% from a year ago.
| Quarter | Spent |
|---|---|
| Q4 2020 | — |
| Q3 2020 | — |
| Q2 2020 | — |
| Q1 2020 | — |
VREX Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +1.4% | +600K shares |
| 1 year | +2.7% | +1.1M shares |
| 3 years | -15% | -7.8M shares |
| 5 years | +3.1% | +1.3M shares |
| Available history | +10% | +4M shares |
VREX has the edge over OSCR on shareholder dilution, with a more favorable share count trend.
OSCR Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | -4.2x | Net Cash |
| Q2 2026 | -5.5x | Net Cash |
| Q1 2026 | -110.0x | Net Cash |
| Q1 2025 | -9.7x | Net Cash |
| Q4 2024 | -13.7x | Net Cash |
| Q3 2024 | -10.1x | Net Cash |
| Q2 2024 | -24.0x | Net Cash |
| Q1 2024 | -217.7x | Net Cash |
OSCR has the edge over VREX on leverage, with a lower net debt burden relative to earnings.
VREX Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q2 2026 | 2.5x | Moderate |
| Q4 2025 | 75.2x | High |
| Q1 2025 | 4.5x | High |
| Q4 2024 | 5.7x | High |
| Q3 2024 | 4.4x | High |
| Q2 2024 | 3.6x | Elevated |
| Q1 2024 | 3.2x | Elevated |
| Q4 2023 | 3.0x | Moderate |
VREX's net debt is about 2.5 years of its operating earnings (EBITDA), down from 4.3 years a year ago.
OSCR Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 58.7 | Neutral |
| Stochastic | 44.9 | Neutral |
OSCR's weekly RSI is 59 (neutral) and its Stochastic is 45 (neutral).
VREX Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 74.5 | Overbought |
| Stochastic | 65.8 | Neutral |
VREX's weekly RSI is 75 (overbought) and its Stochastic is 66 (neutral).
OSCR PE vs Healthcare Sector
| Metric | OSCR | Sector median | Relative |
|---|---|---|---|
| PE | 13x | 26x | 50% below |
| PE % | 3 | 35 | 32 pts below |
OSCR has the edge over VREX on valuation relative to its sector.
VREX PE vs Healthcare Sector
| Metric | VREX | Sector median | Relative |
|---|---|---|---|
| PE | 35x | 26x | 36% above |
| PE % | 65 | 29 | 36 pts above |
VREX is trading at 35x earnings, a 36% premium to the Healthcare sector's median of 26x.
OSCR Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $31.2 | 2.3% above |
| 20 week MA | $31.1 | 2.8% above |
| 50 week MA | $22.9 | 39% above |
| 100 week MA | $19.3 | 65% above |
| 200 week MA | $15.5 | 106% above |
OSCR has the edge over VREX on trend strength, trading above more of its moving averages.
VREX Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $18.4 | 0.8% below |
| 20 week MA | $16.3 | 12% above |
| 50 week MA | $13.5 | 35% above |
| 100 week MA | $12.1 | 51% above |
| 200 week MA | $14.9 | 23% above |
VREX has slipped below its 8-week average, but it's still above the other four, and 23% above its 200-week average.
OSCR Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2021 | $31.0 | $8.02 | -74% |
| 2022 | $8.02 | $2.21 | -72% |
| 2023 | $2.21 | $9.15 | +314% |
| 2024 | $9.15 | $13.8 | +51% |
| 2025 | $13.8 | $14.9 | +8% |
| 2026 YTD | $14.9 | $31.9 | +114% |
OSCR has the edge over VREX on returns for 2026, with the stronger performance.
VREX Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $30.3 | $16.3 | -46% |
| 2021 | $16.3 | $31.8 | +96% |
| 2022 | $31.8 | $19.8 | -38% |
| 2023 | $19.8 | $20.5 | +3.5% |
| 2024 | $20.5 | $14.8 | -28% |
| 2025 | $14.8 | $11.8 | -20% |
| 2026 YTD | $11.8 | $18.3 | +54% |
VREX is up 54% so far in 2026, after finishing lower in four of the previous six years.